BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

GMAB upcoming catalysts

Genmab: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 7 readout(s) and 1 FDA event(s). Subscribe to GMAB (.ics).

Drugs: Pembrolizumab, Paclitaxel, Gemcitabine, Topotecan, Lenalidomide, Cisplatin, Carboplatin, Pemetrexed

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-03-27FDA approvalapprovedGENMAB US, INC. GMABEPKINLYApproved 2026-03-27: EPKINLY (BLA761324 SUPPL10)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-08-18P3Genmab GMABNCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerPlatinum-resistant Ovarian Canceractive not recruiting584
2026-06-10P2Genmab GMABNCT05660967 Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphomaterminated111
2026-05-15P2Genmab GMABNCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With Cutaneous Melanoma; Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, oterminated1
2026-03-30P1/P2Genmab GMABNCT06685068 A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid TumorsAdvanced Solid Tumorterminated23
2026-03-25P1/P2Genmab GMABNCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) TrialBreast Cancer, Breast Neoplasms; Endometrial Cancer, Endometrial Neoplasm; Ovarian Cancer, Ovarian Nterminated179
2025-12-30P1/P2Genmab GMABNCT04083599 GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsMalignant Solid Tumor; Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Melanoma; Head aactive not recruiting350
2025-11-20P1/P2Genmab GMABNCT06391775 Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination TherapyMalignant Solid Tumorterminated21

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.